思创医惠(300078) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 344,101,775.15, representing a year-on-year increase of 14.96%[8] - Net profit attributable to shareholders decreased by 11.19% to CNY 31,920,639.65 compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 10.01% to CNY 29,940,648.58[8] - Basic earnings per share decreased by 11.24% to CNY 0.0395[8] - The weighted average return on net assets was 1.45%, a decrease of 0.28% compared to the previous year[8] - Total operating revenue for the current period reached ¥344,101,775.15, an increase of 14.93% compared to ¥299,334,653.46 in the previous period[36] - Net profit for the current period was ¥31,736,419.41, a decrease of 8.24% from ¥34,531,134.71 in the previous period[37] - The company reported a total profit of ¥34,324,924.56, which is a decrease of 16.38% compared to ¥41,080,968.60 in the last period[37] - The company reported a net profit increase, with retained earnings rising to CNY 619,856,133.57 from CNY 513,136,506.47, an increase of about 20.8%[29] - Net profit for the period was ¥117,449,209.49, representing a 11.5% increase from ¥105,013,108.71 in the previous period[45] Assets and Liabilities - Total assets increased by 4.18% to CNY 3,567,232,933.03 compared to the end of the previous year[8] - The company's total equity reached CNY 2,337,906,840.23, up from CNY 2,246,721,165.69, reflecting an increase of about 4.0%[29] - The total liabilities increased to CNY 1,229,326,092.80 from CNY 1,177,374,537.99, reflecting an increase of approximately 4.4%[28] - Current liabilities decreased to CNY 954,168,092.80 from CNY 982,980,053.87, a reduction of about 2.6%[28] - Long-term borrowings rose to CNY 273,448,500.00, compared to CNY 192,948,000.00, indicating an increase of approximately 41.8%[28] - The company’s total non-current assets amounted to CNY 1,826,612,556.03, up from CNY 1,750,363,689.78, indicating a growth of about 4.4%[27] Cash Flow - The net cash flow from operating activities showed a decline of 32.36%, amounting to CNY -141,699,636.49 for the year-to-date[8] - Cash and cash equivalents decreased by 44.03% to ¥270,219,963.28 from ¥482,794,143.90 due to loan repayments and increased procurement costs[16] - Cash inflow from sales of goods and services was CNY 302,402,506.64, slightly down from CNY 304,281,577.70 in the previous year[55] - The company generated cash flow from operating activities of ¥913,360,665.98, compared to ¥805,129,417.79 in the previous period[51] - Net cash outflow from operating activities was CNY -141,699,636.49, worsening from CNY -107,055,025.71 in the same period last year[52] - Investment activities generated a net cash outflow of CNY -89,050,480.22, compared to CNY -252,909,371.37 in Q3 2018, indicating improved cash flow management[53] - Financing activities resulted in a net cash outflow of CNY -12,228,238.95, a significant decrease from a net inflow of CNY 209,397,090.84 in the previous year[53] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,169[12] - The largest shareholder, Lu Nan, holds 16.33% of the shares, totaling 131,905,000 shares[12] Expenses - Total operating costs amounted to ¥303,923,459.55, up 14.48% from ¥265,461,816.84 in the prior period[36] - Sales expenses rose by 35.57% to ¥89,864,954.69 from ¥66,285,264.96, attributed to expanded sales scale and increased market development costs[16] - Research and development expenses increased to ¥36,202,396.48, representing a rise of 26.38% from ¥28,647,902.35 year-over-year[36] - The company reported a significant increase in sales expenses, which rose to ¥33,251,711.12 from ¥16,280,267.77, marking a 104.06% increase[36] Non-Recurring Items - The company reported a total of CNY 13,445,865.85 in non-recurring gains and losses for the year-to-date[9] - The company experienced a credit impairment loss of ¥14,242,337.41, compared to a loss of ¥1,948,656.71 in the previous period[37] - The company incurred credit impairment losses of ¥17,152,106.83, slightly higher than the previous period's loss of ¥16,185,255.28[45]